Arrowhead price target raised to $54 from $50 at Piper Jaffray Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead to $54 from $50 after the companyhosted an R&D Day on Friday highlighting its TRiM pipeline. The analyst notes that AROANG3 and ARO-APOC3 are advancing to treat diseases characterized by high cholesterol and triglycerides, and anticipates Phase I healthy volunteer SAD data in two late-breaking presentations at AHA on November 18th. Both drugs could begin pivotal studies next year, he adds. Tenthoff reiterates an Overweight on the shares.
Read more at: